Single Dose Double-blind, Placebo-controlled Cross-over (SDDBPCCO) Shiftability Study, Will be Followed by a 10-week Open-label Study With Arbaclofen (4 Weeks of Titration and Then 6 Weeks of Active/Stable Treatment). The Effects of Arbaclofen on Target EEG and ERG Metrics Will be Associated With th

NCT07655115 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

103

Enrollment

OTHER

Sponsor class

Conditions

Autism Spectrum Disorders

Interventions

DRUG: Arbaclofen
OTHER: Placebo

Sponsor

Hospital General Universitario Gregorio Marañon

Collaborators

[object Object]